Chemocentryx patents expiration
1. Tavneos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(6 years from now) | |
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(7 years from now) | |
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2028 |
| New Chemical Entity Exclusivity (NCE) | Oct 7, 2026 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 2025-10-07
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE;ORAL
More Information on Dosage
TAVNEOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic